EE493 Cost-Effectiveness of Pembrolizumab+Lenvatinib for Treatment of Advanced Endometrial Carcinoma in Women Who Have Progressed Following Prior Systematic Therapy and Are Not Candidates for Curative Surgery or Radiation in France

Autor:	M Fabbro, L Cagnan, F Midy, S Comps, L Bensimon, A Merchant, V Prabhu, K Young
Rok vydání:	2022
Předmět:	Health Policy Public Health Environmental and Occupational Health
Zdroj:	Value in Health. 25:S152-S153
ISSN:	1098-3015
DOI:	10.1016/j.jval.2022.09.736
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::42c502649ddae8690f66030b199b66de https://doi.org/10.1016/j.jval.2022.09.736 Zobrazit plný text záznamu Full Text from ScienceDirect